Zanubrutinib Combined With G-CVP in Previously Untreated FL

Inclusion Criteria: Patients must meet all of the following criteria to be eligible: 1\. Histologically confirmed CD20-positive FL (grades 1, 2, or 3a), diagnosed according to the WHO 2022 criteria; 2, Clear indication for treatment: symptoms affecting normal work and life; end-organ dysfunction; cytopenia due to bone marrow involvement by lymphoma; bulky disease (per GELF criteria); persistent or rapidly progressive disease; 3. No prior systemic therapy for lymphoma; 4. Age 18-80 years; 5. Eastern cooperative oncology group (ECOG) performance status (PS) \< 2; 6. Expected survival \> 2 years; 7. At least one measurable lesion with a longest diameter ≥ 1.5 cm or extranodal lesion ≥ 1 cm; 8. Willingness to participate in the study and comply with treatment and follow-up. Exclusion Criteria: Patients will be excluded if they meet any of the following criteria: 1. Pregnant or breastfeeding women; 2. Abnormal liver or kidney function, defined as: serum direct/indirect bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum creatinine \> 2 × upper limit of normal (ULN); creatinine clearance \< 60 mL/min (unless due to lymphoma involvement); 3. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months; 4. Absolute neutrophil count (ANC) \< 1.5 × 10⁹/L, platelets \< 75 × 10⁹/L, or hemoglobin \< 70 g/L (unless due to bone marrow involvement by lymphoma); 5. Long-term use of strong or moderate CYP3A inducers; 6. Known hypersensitivity to any component of the study drug; 7. Other active malignancies, except: cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, or other malignancies with disease-free survival \> 5 years; 8. Severe concurrent infections; 9. Drug abuse, medical, psychological, or social conditions that may interfere with study participation or result evaluation; 10. Investigator-deemed ineligibility for the study.